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ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous 
malignancy, with highly variable outcomes among patients. Although classification 
and prognostic tools have been developed, standard therapy still fails in 30-40% of 
patients. Hence, identification of novel biomarkers is needed. Recently, circulating 
microRNAs (miRNAs) have been suggested as non-invasive biomarkers in cancer. 
Our aim was to review the potential role of circulating miRNAs as biomarkers for 
diagnosis, classification, prognosis, and treatment response in DLBCL.
We performed a search in PubMed using the terms [((‘Non-coding RNA’) OR 
(‘microRNA’ OR ‘miRNA’ OR ‘miR’) OR (‘exosome’) OR (‘extracellular vesicle’) OR 
(‘secretome’)) AND (‘Diffuse large B cell lymphoma’ OR ‘DLBCL’)] to identify articles 
that evaluated the impact of circulating miRNAs as diagnosis, subtype, treatment 
response or prognosis biomarkers in DLBCL in human population.
Among the twelve articles that met the inclusion criteria, eleven considered 
circulating miRNAs as biomarkers for diagnosis, two for classification, and five for 
prognosis or treatment response. The limited number of studies performed and lack of 
consistency in results make it difficult to draw conclusions about the role of circulating 
miRNAs as non-invasive biomarkers in DLBCL. Although the preliminary associations 
observed seem promising, the only consistent result is the upregulation of mir-21 in 
DLBCL patients, which could be a biomarker for diagnosis. Further studies are needed.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the 
most common subtype of non-Hodgkin lymphoma 
(NHL), accounting for 30% to 40% of all newly diagnosed 
cases [1]. DLBCL is an aggressive malignancy, very 
heterogeneous in genetic abnormalities, clinical features 
and response to treatment. This heterogeneity results in 
highly variable outcomes among patients [2].
Combined chemotherapy of rituximab, 
cyclophosphamide, doxorubicin, vincristine, and 
prednisone (R-CHOP) is considered as the standard first 
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line therapy for DLBCL. The application of R-CHOP 
has led to complete remission for 75-80% of patients 
[3]. However, 30-40% of patients that achieve complete 
remission relapse at a later stage and some patients have 
refractory disease. Alarmingly, those patients tend to 
respond poorly to additional chemotherapy lines [4].
In order to predict the outcome of patients with 
DLBCL, different tools have been developed. For 
instance, the International Prognostic Index (IPI) 
identifies four risk groups with predicted five-year 
survival ranging from 26% to 73% using different clinical 
factors (age, stage, serum LDH, ECOG performance 
status and number of extranodal sites) [5]. Nevertheless, 
some patients present an unfavorable course of disease 
despite a good prognostic index. Another molecular 
prognostic tool uses gene expression profiling (GEP) 
and immunohistochemical analysis to discriminate two 
molecular subtypes with different clinical outcomes 
independent of IPI stratification: the germinal center 
B-cell-like (GCB) DLBCL, and the activated B-cell-like 
(ABC) DLBCL, with 5-year survival rates of 60% and 
35% respectively [6, 7]. However, these tools are not able 
to identify all the patients that will not respond to therapy 
and, hence, novel biomarkers to enable a better prognostic 
stratification are needed.
During the past decades, several novel molecular 
and biological candidates with diagnostic, predictive and 
prognostic potential in DLBCL have been suggested, 
including microRNAs (miRNAs). MiRNAs are small, 
regulatory, non-coding RNAs that can negatively 
regulate gene expression at the post-transcriptional 
level by binding to the 3´ untranslated region (UTR) 
of a target mRNA and leading to increased degradation 
or inhibition of translation [8]. Nowadays, hundreds of 
miRNAs have been identified as biomarkers in cancer 
[9–11]. Interestingly, recent evidence has emerged 
showing that tumor-associated miRNAs can also be 
detected in body fluids such as serum or plasma [12]. 
This is possible thanks to the fact that miRNAs are 
protected from degradation in serum or plasma through 
association with RNA-binding proteins and/or packaging 
inside extracellular vesicles [13], providing them with 
high stability. This characteristic makes it possible to use 
non-invasive techniques for their evaluation, which is a 
great advantage regarding disease monitoring. Therefore, 
circulating miRNAs have emerged as candidate non-
invasive biomarkers for diagnosis, and prognosis in cancer 
[14–17].
To date, some groups have investigated the potential 
role of circulating microRNAs in DLBCL [18–28]. 
Nevertheless, these studies present controversial results. 
We considered that it would be of interest to clarify these 
discrepancies. Therefore, herein, we review the potential 
role of circulating miRNAs as biomarkers for diagnosis, 
subtype characterization, prediction of treatment response 
and prognosis in patients with DLBCL.
RESULTS
A total of 487 records were initially identified (Figure 
1). Among them, 328 records remained after duplicates 
were removed. Among these records, 211 were discarded 
after abstract review because they clearly did not meet the 
required inclusion criteria. The full texts of the remaining 
117 studies, which studied miRNAs in human DLBCL, 
were examined in detail. Further 104 articles were excluded 
because they were focused in tumor tissue and did not 
include circulating miRNAs, were focused in specific groups 
of patients with additional pathologies, or did not analyze 
microRNAs as diagnosis, subtype, treatment response, or 
prognosis biomarkers. After reviewing the references of 
the identified articles, one additional study was included. 
Finally, 12 articles investigating the role of circulating 
miRNAs as biomarkers in DLBCL were included. Eleven 
of them considered miRNAs as putative DLBCL diagnosis 
biomarkers, two articles searched for markers for subtype 
classification, and five articles considered treatment 
response or prognosis as their endpoint.
Circulating miRNAs as non-invasive biomarkers 
for diagnosis in DLBCL
Eleven articles searched for circulating miRNAs 
deregulated in DLBCL patients vs. healthy controls (Table 
1) [18-20, 22-29]. Those deregulated miRNAs could be 
used as biomarkers for diagnosis in this malignancy.
Considering common miRNAs analyzed across 
different studies, we only identified seven miRNAs found 
to be significantly deregulated in DLBCL patients in at 
least two studies (miR-15a, miR-21, miR-29c, miR-34a, 
miR-145, miR-155, and miR-210) (Table 2) [18-20, 22-
29]. Among them, five miRNAs showed conflicting 
results. On the one hand, miR-29c and miR-34a were 
found contradictorily upregulated or downregulated in 
DLBCL patients in different studies. On the other hand, 
miR-15a, miR-155 and miR-210 were found upregulated 
or unchanged in patients in the different studies in which 
they were analyzed.
Promisingly, other two miRNAs showed more 
homogeneous results. For instance, miR-145 was 
consistently downregulated in DLBCL patients. However, 
it must be noted that this result was only supported by the 
two studies in which it was studied [24, 28]. Interestingly, 
miR-21 was found accordingly upregulated in six of the 
eight studies in which it was analyzed [18, 20, 23, 24, 
26, 29], pointing to this miRNA as a potential diagnosis 
biomarker in DLBCL.
Circulating miRNAs as non-invasive biomarkers 
for subtype classification in DLBCL
The potential role of circulating microRNAs in 
DLBCL classification has been analyzed in a limited 
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set of only two studies (Table 3) [20, 21]. A total of six 
microRNAs were studied comparing patients with ABC 
and GCB subtypes to search for differences among 
them. Each miRNA was analyzed in only one study. 
Among them, only miR-21 was found to be differentially 
expressed between subtypes, being upregulated in the 
subgroup of patients with ABC subtype [20].
Circulating miRNAs as non-invasive biomarkers 
for prediction of response to R-CHOP therapy in 
DLBCL
Only two studies have focused in circulating 
miRNAs as predictive biomarkers of response to R-CHOP 
treatment in DLBCL patients [21, 24] (Table 4).
The first study analyzed 736 miRNAs in serum 
samples of 20 complete remission and 20 primarily 
refractory DLBCL patients. Five miRNAs were 
differentially expressed between both groups (miR-224, 
miR-1236, miR-520d-3p, miR-33a, and miR-455-3p) and 
were validated in an independent group of 133 patients. 
Upregulation of miR-455-3p and miR-33a was found to 
be associated with chemosensitivity while upregulation 
of miR-224, miR-1236, and miR-520d-3p was associated 
with chemoresistance [21].
The second study analyzed a group of eight miRNAs 
(miR-21, miR-29, miR-125b, miR-130a, miR-145, miR-
155, miR-200c and miR-451) finding the upregulation of 
miR-125b and miR-130a to be associated with resistance 
to R-CHOP treatment [24].
MiR-21 was the only miRNA analyzed in both 
studies. Nevertheless, its expression was not significantly 
associated with treatment response in any of the two 
studies.
Circulating miRNAs as non-invasive biomarkers 
for prognosis prediction in DLBCL
Finally, the relevance of circulating microRNAs for 
prognosis prediction in DLBCL patients was considered 
in five studies [18, 20, 21, 23, 24] (Table 5). A total of ten 
microRNAs were analyzed. Among them, only miR-21 
Figure 1: Flowchart of study selection.
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Table 1: Circulating miRNAs as non-invasive biomarkers for diagnosis in DLBCL
miRNAs Result Sample miRNA source(method) Method Reference
159 miRNAs
miR-124
miR-532-5p
miR-122
miR-128
miR-141
miR-145
miR-197
miR-345
miR-424
miR-425
miR-101
miR-324
let-7e
miR-222
miR-29c
miR-375
miR-324-5p
miR-135a
miR-379
let-7i*
miR-32
Other
upregulation 
upregulation 
downregulation
downregulation 
downregulation 
downregulation 
downregulation 
downregulation 
downregulation 
downregulation 
downregulation 
downregulation 
downregulation 
downregulation 
downregulation 
downregulation 
downregulation 
downregulation 
downregulation 
downregulation 
downregulation 
NS
14 DLBCL vs. 20 
controls
Plasma/plasma 
exosomes (RNeasy 
MinElute)
Illumina HISeq 
sequencing
Khare D, et al 
(2017) [28]
2588 miRNAs
miR-34a-5p
miR-323b-3p
miR-431-5p
51 DEMs
upregulation 
downregulation 
downregulation
3 DLBCL vs.
3 controls
Serum
(miRcute, 
Tiangen)
Illumina HISeq 
sequencing and 
qRT-PCR
(SYBR Green)
Meng Y, et al 
(2017) [27]
miR-21 upregulation 203 DLBCL vs. 100 controls
Serum
(miRNeasy
Serum/Plasma)
qRT-PCR
(miScript SYBR 
Green)
Zheng Z, et al. 
(2017) [26]
miR-155 NS 5 DLBCL vs.18 controls
Serum 
extracellular 
vesicles
(mirVana PARIS)
qRT-PCR
(TaqMan)
Caivano A, et al. 
(2017) [25]
miR-21
miR-125b
miR-130a
miR-155
miR-200c
miR-29c
miR-145
miR-451
upregulation 
upregulation 
upregulation 
upregulation 
upregulation
downregulation
downregulation 
downregulation
56 DLBCL vs. 20 
controls
Serum
(miRcute, 
Tiangen)
qRT-PCR
(miRcute, 
Tiangen).
Yuan WX, et al. 
(2016) [24]
miR-21 upregulation 112 DLBCL vs. 45 controls
Serum
(Trizol)
qRT-PCR
(TaqMan 
microRNA)
Li J, et al (2015) 
[23]
miR-17
miR-20b
miR-210
miR-296
NS
NS
NS
NS
21 DLBCL vs. 6 
controls
Serum
(miRNeasy Serum/
Plasma)
qRT-PCR
(TaqMan Small 
RNA)
Borges NM, et al. 
(2016) [22]
(Continued )
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was studied in more than one article, providing discordant 
results. Upregulated miR-21 has been described as an 
independent poor prognostic factor in one of the studies 
[23]. However, the other two studies [18, 20] have 
shown its upregulation associated with good prognosis. 
Regarding the other miRNAs, which were analyzed each 
of them by an only study, upregulation of miR-125b was 
found to be associated with poor prognosis in patients with 
DLBCL [24]. On the other hand, high expression of miR-
224, miR-1236, and miR-520d-3p and low expression of 
miR-455-3p and miR-33a were found to be individually 
associated with unfavorable outcome and a score based 
on this five-miRNAs was proposed to predict the clinical 
outcome of DLBCL patients treated with R-CHOP 
regimen, independent from the IPI score [21].
DISCUSSION
In this systematic review, we have performed a deep 
analysis of the current literature in relation to the potential 
role of circulating miRNAs as non-invasive biomarkers 
for diagnosis, subtype characterization, treatment response 
and prognosis in patients with DLBCL.
Regarding the suitability of circulating miRNAs as 
diagnostic biomarkers in DLBCL, eleven articles were 
identified, in which a total of seven miRNAs (miR-15a, 
miR-29c, miR-34a, miR-155 and miR-210) were found 
at least twice to be significantly deregulated in DLBCL 
patients [18-20, 22-29]. Among them, only miR-145 and 
miR-21 presented concordant results. Contradictory results 
could be due to different factors, including differences in 
methodology, or miRNA source, though in these studies 
those factors are quite homogeneous. On the other hand, 
it must be noted that most studies were performed with 
limited sample sizes and statistical power. Consequently, 
further larger studies are needed to clarify the results.
MiR-145, which was downregulated in DLBCL 
patients in the two studies in which it was analyzed [24, 
28], is a tumor-suppressor miRNA that has been found to 
be downregulated in several cancer types, i.e. colorectal 
cancer, bladder cancer, or ovarian cancer [30–32]. In 
fact, some of the validated targets of this miRNA include 
known hallmarks of DLBCL, such as c-MYC or ETS1 
[33–39]. However, such a limited number of studies 
with modest sample sizes does not allow to reach final 
conclusions. Further studies would be required in order 
to validate the putative role of mir-145 as a non-invasive 
biomarker for diagnosis in DLBCL.
On the other hand, it is noteworthy that miR-21, 
which was analyzed in eight independent studies, was 
miRNAs Result Sample miRNA source(method) Method Reference
miR-15a-3p
miR-21-5p
miR-210-5p miR-
181a-5p
miR-155-5p
miR-210-3p
upregulation 
upregulation 
upregulation
downregulation 
NS
NS
33 DLBCL vs. 22 
controls
Serum
(mirVana PARIS)
qRT-PCR
(TaqMan 
microRNA)
Inada, et al (2015) 
[29]
miR-21 upregulation 62 DLBCL vs. 50 controls
Serum
(mirVana)
qRT-PCR
(TaqMan 
microRNA)
Chen W, et al 
(2014) [20]
miR-15a
miR-16-1
miR-29c
miR-155
miR-34a
miR-21
miR-223
upregulation
upregulation 
upregulation
upregulation
downregulation 
NS
NS*
75 DLBCL vs. 77 
controls
Serum
(Trizol)
qRT-PCR
(SYBR Green)
Fang C, et al 
(2012) [19]
miR-21
miR-155
miR-210
upregulation 
upregulation 
upregulation
60 DLBCL vs. 43 
controls
Serum
(Trizol)
qRT-PCR
(Taqman 
microRNA)
Lawrie CH, et al. 
(2008) [18]
upregulation: Significantly increased expression in DLBCL patients.
downregulation: Significantly decreased expression in DLBCL patients.
NS: no significant difference in expression between patients and controls.
DEM: differentially expressed miRNAs.
*: analyzed in a subset of 20 patients vs. 20 controls.
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significantly upregulated in DLBCL patients in six of 
them [18, 20, 23, 24, 26, 29]. In agreement with this 
observation, miR-21 is one of the most frequently up-
regulated miRNAs in solid tumors and high levels are 
also observed in B-NHLs, being considered an oncomiR. 
In fact, overexpression of miR21 experimentally leads 
to a pre-B malignant lymphoid-like phenotype [40]. In 
addition, miR-21 has been described as a key regulator of 
disease progression in B-cell lymphoma [41]. Its role in 
tumorigenesis and disease progression has been associated 
to the inhibition of the expression of phosphatases, 
limiting the activity of signaling pathways such as PI3K/
AKT, recently suggested to play a crucial role in mediating 
growth, proliferation and cell survival in a substantial 
number of DLBCL patients [42, 43]. In summary, the 
biological role of miR-21 and its replicated upregulation 
in circulating fluids suggest that miR-21 could be a good 
biomarker for DLBCL diagnosis.
The utility of circulating microRNAs for DLBCL 
classification has been analyzed by only two studies with 
no coincidence in the miRNAs considered [20, 21]. Only 
miR-21 was found to be upregulated in the ABC subgroup, 
which is associated with lower survival, in a subset of 62 
DLBCL patients [20]. Since this association was observed 
in only one study with a limited sample size, it would need 
to be further explored by additional research.
Focusing on circulating miRNAs as predictive 
biomarkers of response to R-CHOP treatment, two studies 
were identified [21, 24]. The only miRNA analyzed in both 
investigations, mir-21, was not associated with treatment 
response in any of the studies. Interestingly, among the 736 
miRNAs analyzed in the first study, upregulation of miR-
455-3p and miR-33a was associated with chemosensitivity 
while upregulation of miR-224, miR-1236, and miR-
520d-3p was associated with chemoresistance [21]. In the 
second study, eight miRNAs were analyzed, finding the 
upregulation of miR-125b and miR-130a to be associated 
with R-CHOP chemoresistance [24]. These results would 
need to be confirmed in additional studies.
Finally, the implication of circulating microRNAs 
in prognosis in DLBCL has been analyzed in five studies 
including ten miRNAs [18, 20, 21, 23, 24]. Among them, 
only miR-21 has been studied in more than one study. 
However, the results for this miRNA are contradictory. On 
the one hand, a multivariate analysis, showed upregulated 
miR-21 as an independent poor prognostic factor [23]. 
Table 2: Circulating miRNAs explored by 2 or more studies as non-invasive biomarkers for diagnosis in DLBCL
miRNAs upregulation downregulation NS
miR-15a [19, 29]  [28]
miR-21 [18, 20, 23, 24, 26, 29]  [19, 28]
miR-29c [19] [24, 28]  
miR-34a [27] [19] [28]
miR-145  [24, 28]  
miR-155 [18, 19, 24]  [25, 29]
miR-210 [18, 29]  [22, 28, 29]
upregulation: Significantly increased expression in DLBCL patients.
downregulation: Significantly decreased expression in DLBCL patients.
NS: no significant difference in expression between patients and controls.
Table 3: Circulating miRNAs as non-invasive biomarkers for ABC/GCB subtype classification in DLBCL
miRNAs Result Sample miRNA source Method Reference
miR-33a
miR-224
miR-455-3p
miR520d-3p
miR-1236
NS
NS
NS
NS
NS
173 DLBCL
(81 ABC vs 92 
GCB)
Serum
(Trizol)
qRT-PCR
(TaqMan microRNA)
Song G, et al. (2014) 
[21]
miR-21 upregulation
62 DLBCL
(30 ABC vs 32 
GCB)
Serum
(mirVana)
qRT-PCR
(TaqMan microRNA)
Chen W, et al (2014) 
[20]
upregulation: Significantly increased expression in ABC subtype.
NS: no significant difference in expression between subtypes.
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Table 4: Circulating miRNAs as non-invasive biomarkers for prediction of of response to R-CHOP therapy in 
DLBCL
miRNAs Result Sample miRNA source Method Reference
miR-125b
miR-130a
miR-21
miR-29c
miR-145
miR-155
miR-200c
miR-451
upregulation
upregulation
NS*
NS*
NS*
NS*
NS*
NS*
56 DLBCL
(21 resistant vs 35 
sensitive)
Serum
(miRcute, 
Tiangen)
qRT-PCR
(miRcute, Tiangen).
Yuan WX, et al. 
(2016) [24]
736 miRNAs
miR-224
miR-520d-3p
miR-1236
miR-33a
miR-455-3p
Other**
upregulation 
upregulation 
upregulation 
downregulation 
downregulation 
NS
133 DLBCL Serum(Trizol)
qRT-PCR
(TaqMan microRNA)
Song G, et al. (2014) 
[21]
upregulation: Significantly increased expression in drug resistant DLBCL patients.
downregulation: Significantly decreased expression in drug resistant DLBCL patients.
NS: no significant difference in expression between resistant and sensitive patients.
*Studied in a subgroup of 20 DLBCL (10 chemo-resistant vs 10 chemo-sensitive).
**Studied in a subgroup of 40 DLBCL (20 chemo-resistant vs 20 chemo-sensitive).
Table 5: Circulating miRNAs as non-invasive biomarkers for prognosis prediction in DLBCL
miRNAs Result Outcome Sample miRNA source Method Reference
miR-125b
miR-130a
-
NS OS 56 DLBCL
Serum
(miRcute, 
Tiangen)
qRT-PCR
(miRcute, Tiangen).
Yuan WX, et al. 
(2016) [24]
miR-21 - OS 112 DLBCL Serum(Trizol)
qRT-PCR
(TaqMan 
microRNA)
Li J, et al 
(2015) [23]
miR-33a
miR-455-3p
miR-224
miR-520d-3p
miR-1236
+
+
-
_
_
MRT/PR 133 DLBCL Serum(Trizol)
qRT-PCR
(TaqMan 
microRNA)
Song G, et al. 
(2014) [21]
miR-21 + RFS 62 DLBCL Serum(mirVana)
qRT-PCR
(TaqMan 
microRNA)
Chen W, et al 
(2014) [20]
miR-21
miR-155
miR-210
+*
NS
NS
RFS / OS 52 DLBCL Serum(Trizol)
qRT-PCR
(Taqman 
microRNA)
Lawrie CH, 
et al. (2008) 
[18]
OS: overall survival; MRT: median remission time; PR: probability of remission; PFS: progression free survival ; RFS: 
relapse free survival; -: high expression of the miRNA significantly associated with worse outcome; +: high expression 
of the miRNA significantly associated with better outcome; * statistically significant association with better RFS but no 
significant association with OS.
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Table 6: Clinical characteristics of the study population in each included study
 Study  Sample
Age Sex (%) Hans’ algorithm (%)
Performance 
status (%)
Ann Arbor 
staging (%) IPI (%) 
Median 
(range) 
or mean 
± SD
Female Male GCB non-GCB nap PS 0-2
PS 
3-4 I II III IV 0-2 3-5
Khare 
D, et al 
(2017) 
[28] 
14 
DLBCL
64 (34-
85) 36 64 NA NA NA NA NA NA NA NA NA 50 50
20 
controls
37 (26-
63) 45 55            
Meng 
Y, et al 
(2017) 
[27] 
3 
DLBCL NA NA NA NA NA NA NA NA NA NA NA NA NA NA
3 
controls NA NA NA            
Zheng 
Z, et al. 
(2017) 
[26] 
203 
DLBCL NA 39.4 60.6 NA NA NA NA NA 56.7  43.3  66 34
100 
controls NA NA NA            
Caivano 
A, et al. 
(2017) 
[25] 
5 
DLBCL
66 
(53–80) 60 40 NA NA NA NA NA NA NA NA NA NA NA
18 
controls
60 
(43–77) 55.6 44.4            
Yuan 
WX, 
et al. 
(2016) 
[24] 
56 
DLBCL
54.7 
(23-74) 43 57 NA NA NA NA NA 10 24 38 28 28 72
20 
controls NA NA NA            
Li J, 
et al 
(2015) 
[23] 
112 
DLBCL NA 48.2 51.8 NA NA NA NA NA 42  58  37.5 62.5
45 
controls NA NA NA            
Borges 
NM, 
et al. 
(2016) 
[22]
21 
DLBCL NA NA NA NA NA NA NA NA NA NA NA NA NA NA
6 
controls NA NA NA            
Inada, 
et al 
(2015) 
[29]
33 
DLBCL
67 (36-
84) 39 61 42.4 48.5 9.1 91 9 9.1 21.2 18.2 51.5 55.6 45.4
22 
controls
62 (20-
76) 41 59            
Chen 
W, et al 
(2014) 
[20]
62 
DLBCL
66.1 
±13.6 33.8 66.1 51.6 48.4 0 NA NA 30.7 17.7 19.3 32.3 71 29
50 
controls NA NA NA            
(Continued )
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On the contrary, the other two studies that considered this 
miRNA have found its upregulation to be associated with 
good prognosis [18, 20]. Surprisingly, in the first of these 
studies, upregulation of miR-21 was also associated with 
ABC-DLBCL subgroup, which usually behaves more 
aggressively and is associated with worse outcome [20]. 
A possible explanation for this apparently contradictory 
situation is that serum miR-21 expression was higher 
in patients with DLBCL stage I and II in comparison 
to those with III and IV, which could be a confounding 
factor. On the other hand, Lawrie et al also showed miR-
21 upregulation associated with good prognosis [18]. 
In this case, even though no multivariate analysis was 
performed, no association between microRNA levels and 
clinicopathological features was observed (i.e. sex, IPI, 
stage and presence of extranodal disease). As a result, the 
significance of miR-21 in prognosis of DLBCL remains 
uncertain.
Focusing in miRNAs analyzed by a single study, 
upregulation of miR-125b has been associated with poor 
prognosis [24]. In addition, a predictor score based on a 
signature of five miRNAs, among which high expression 
of miR-224, miR-1236, and miR-520d-3p and low 
expression of miR-455-3p and miR-33a were individually 
associated with unfavorable outcome, has been proposed 
to predict the clinical outcome of DLBCL patients, 
independent from the IPI score [21]. However, all these 
results need to be confirmed, given the limited evidence 
provided.
In brief, the limited number of studies performed, 
which usually consider a limited set of miRNAs, and the 
lack of consistency in the results obtained make it difficult 
to draw final conclusions about the role of circulating 
miRNAs as non-invasive biomarkers in DLBCL. 
Although the preliminary associations observed could 
be of interest, the only result that seems sounder so far 
is the upregulation of mir-21 in DLBCL patients, which 
could be used for diagnosis. Consequently, it would be of 
particular interest to perform large-scale studies including 
larger sample sizes and a wider array of miRNAs. We 
can conclude that even if this is a very promising field 
of study, published evidence is very limited and further 
studies are needed.
MATERIALS AND METHODS
A systematic search in PubMed database was 
performed to identify articles published between 
November 1975 and November 2017 using the following 
strategy: [((‘Non-coding RNA’) OR (‘microRNA’ OR 
‘miRNAs’ OR ‘miR’) OR (‘exosome’) OR (‘extracellular 
vesicle’) OR (‘secretome’)) AND (‘Diffuse large B cell 
lymphoma’ OR ‘DLBCL’)].
Articles were included if they presented independent 
original studies and evaluated the impact of circulating 
miRNAs as diagnosis, subtype, treatment response or 
prognosis biomarkers in DLBCL in human population. 
Reviews and meta-analyses, case reports, letters, 
comments, abstracts, and articles not published in English 
were not included. Studies were also excluded if they did 
not analyze miRNAs, did not include data from human 
populations, or were focused on other diseases. After full 
 Study  Sample
Age Sex (%) Hans’ algorithm (%)
Performance 
status (%)
Ann Arbor 
staging (%) IPI (%) 
Median 
(range) 
or mean 
± SD
Female Male GCB non-GCB nap PS 0-2
PS 
3-4 I II III IV 0-2 3-5
Fang 
C, et al 
(2012) 
[19]
75 
DLBCL
54 
(19–85) 45.3 54.7 NA NA NA NA NA 13.3 16 22.7 48 60 40
77 
controls
50 
(36–68) 41.5 58.4            
Lawrie 
CH, 
et al. 
(2008) 
[18]
60 
DLBCL 63 ±11 35 65 NA NA NA NA NA 33 23 30 13 70 30
43 
controls NA NA NA            
Song 
G, et al. 
(2014) 
(21)
173 
DLBCL
56.4 
(19-78) 47.4 52.6 53.2 46.8 0 85.5 14.5 14.5 25.4 35.3 24.8 22.3 67.7
NA: Data not available. Nap: unclassified.
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text assessment, articles that did not analyze circulating 
miRNAs, included other diseases, or did not assess the 
role of miRNAs in diagnosis, subtype, treatment response, 
or prognosis, were excluded. All references within the 
identified studies were then reviewed in order to identify 
additional matches.
Each eligible manuscript was assessed 
independently by two researchers (ML and AL). 
Disagreements were resolved by consensus. Data 
extracted from each study included: publication year, 
type of blood-based fluid analyzed (serum or plasma), 
characteristics of the study population (Table 6), technical 
methodology, miRNAs assessed, and the list of specific 
miRNAs that could be used as biomarkers in DLBCL. 
In order to define associations between the expression of 
the miRNAs and the phenotypes, a p value < 0.05 was 
considered statistically significant.
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